Tag Archives: Fortune

20 States accuse Mylan, Teva, others of price fixing; what a banner week for the legal profession

Peggy_Marco / PixabayOne day after federal prosecutors unsealed a criminal indictment against the former CEO of Heritage Pharmaceuticals Inc. (Eatontown NJ), 20 state attorneys general filed an antitrust lawsuit against… Read more »

US Senate joins House to pass sweeping new health bill; could be the last bi-partisan act of Congress for quite a while

The US Senate voted overwhelmingly on Wednesday (December 7, 2016) to support sweeping legislation that will reshape the way the Food and Drug Administration approves new medicines. It will also… Read more »

Arrowhead Pharma obliterated after ditching Hep B candidate; oh, that’s right, biotechs are risky

Shares of Arrowhead Pharmaceuticals Inc. (Pasadena CA) cratered 69% to $1.44 last week (November 28 to December 2, 2016) after the company said it would stop developing all drugs being… Read more »

Lilly Alzheimer’s drug, like so many others, fails; will true breakthrough happen this century?

Eli Lilly & Co. (Indianapolis RIN) said its experimental Alzheimer’s treatment failed to slow loss of cognitive ability in patients with mild symptoms, a major setback for the company and millions of… Read more »

Obamacare startup Oscar racks up $45-million 3Q Loss; Trump’s healthcare agenda meddling with in-law’s $2.7-billion bet

Oscar Insurance Corp. (New York City), the Silicon Valley-backed healthcare startup, continued to lose tens of millions of dollars in the third quarter as the company exits some markets and works… Read more »

Valeant stock plunges anew on dismal 3Q results; behold another pharma Sisyphus

After an already noisy year, Valeant Pharmaceuticals International Inc. (Laval Québec) once again took investors off guard–this time, on Election Day–as new management cut the annual profit forecast to well… Read more »

Mylan CEO Bent Truth About Epipen Profit; Sadly Follows Path of Valeant, Turing Pharma

Controversial Mylan NV (Amsterdam) CEO Heather Bresch was grilled in a marathon committee hearing about the EpiPen’s pricing before Congress last week. But it turns out that several of her… Read more »

Mylan Reportedly Paid Its Top Execs More than Industry Giants

Mylan, the Amsterdam-based company facing copious scrutiny from the media, consumers and politicians for its drug pricing practices, ranks second-highest among all U.S. drug and biotech firms in executive compensation,… Read more »

Theranos Pulls Zika Test from FDA Review after Problems Flagged; Anyone Else Hear a Death Knell?

Blood-testing firm Theranos Inc. (Palo Alto CA) said it voluntarily withdrew a request to the U.S. Food and Drug Administration for emergency clearance of its new Zika-virus blood test. Theranos… Read more »

HHS Can’t Wait for Congress; Shifts $81 Million from NIH for Zika Fight

The U.S. Department of Health and Human Services has shifted $81 million in funds from other projects to continue work on developing vaccines to fight the Zika virus in the absence of… Read more »